Sobi Reports Strong 2Q Gamifant Sales as Hemophilia Competition Enters Market
We're not expecting to make any significant changes to our SEK 240 per share fair value estimate for Sobi following a strong second quarter, as the firm's hemophilia franchise continues to hold up in Europe, and Gamifant's launch in the U.S. appears to be on track. Our valuation factors in a 50% probability that the firm is acquired at a 7 times multiple to 2019 sales, or roughly SEK 300 per share. While near-term sales and margins are benefiting from hemophilia product demand and the addition o...Swedish Orphan Biovitrum AB is a healthcare company focused on rare diseases. Co. develops, manufactures and commercializes treatments with a particular focus on four therapeutic areas: Inflammation, Genetics & Metabolism, Haemophilia and Neonatology. Co. also markets a portfolio of rare disease products for partner companies. Co.'s pipeline programmes include research and development focused on recombinant protein drugs in late preclinical and clinical phase for indications.
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.